331 West 57th Street #332
New York, NY 10019
877.751.5400
info@canliv.org
A copy of CanLiv's latest financial report may be obtained from:
Charities Bureau, Office of the New York State Attorney General
Attn: FOIL Officer
120 Broadway
New York, NY 10271
Hepatocellular Carcinoma
Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336(26):1855-9.
Llovet, JM, Ricci S, Mazzaferro V, et al. Sorafenib in Advanced Hepatocelluar Carcinoma. N Engl J Med 359:378-390, 2008
Nair S, Mason A, Eason J, et al: Is obesity an independent risk factor for hepatocellular carcinoma? Hepatology 36: 150155, 2002
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557-76.
El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127(5 Suppl 1):S27-34.
Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005;97(4):293-300.
Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998;28(4):921-5.
Legal | Disclaimer | Privacy | All rights reserved. © 2010 by CanLiv, The Hepatobiliary Cancers Foundation
